Bayer Collaborates with Children’s Hospital of Philadelphia to Develop Oral Non-Replacement Therapy for the Treatment of Hemophilia
Bayer Collaborates with Children’s Hospital of Philadelphia to Develop Oral Non-Replacement Therapy for the Treatment of Hemophilia A and B
Shots:
- Bayer to invest $5M in the three-year collaboration with an option to extend the collaboration, if agreed by both the companies. The companies will jointly develop a first-in-class oral small molecule-based NRT for the treatment of hemophilia A and B
- Bayer to get an option to license the product developed under the collaboration. The agreement will integrate CHOP’s expertise in hemophilia and coagulation with Bayer’s research capabilities
- The alliance has the potential to change the treatment paradigm for patients with hemophilia. Additionally, Bayer is currently working to develop gene therapy for hemophilia A patients which may reduce the frequency of treatment
Click here to read full press release/ article | Ref: Bayer | Image: Reuters